Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 FY21 Sales per region Full Year Results Highlights Genetic Signatures finished the year with record revenue of $28.3m, 151% higher than FY2020 which was also a record. SARS-CoV-2 diagnostic kit sales drove the larger share of revenue though demand for enteric kits has returned to pre-pandemic levels. Instrument sales and reagent rentals were $1.5m for the year. The number of Genetic Signatures’ branded instruments in use has quadrupled since before the pandemic. Overseas sales were 21% of overall revenue, up from 10% the previous year. In $ terms this represents a six-fold increase in the contribution from Europe and USA to $6m. Europe saw multiple new sites added during the year while in the USA the Company’s first customers were recruited. SARS-CoV-2 testing volumes in both regions have declined from their peak in December 2020 attributable largely to successful vaccine programs. While testing is increasing again in the first quarter of FY2022 it is unclear if this will result in an increased number of PCR tests being performed. Australia, representing the vast majority of current sales due to time in this market, increased revenue significantly and this momentum has continued into FY2022. Revenue from operations ($m) 4-year CAGR = 93% FY18 2.8 FY19 4.9 FY20 FY20 11.3 28.3 AMERICAS 6% ASIA PACIFIC 79% EMEA 15%